We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+19.47%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$285M
AUM Growth
-$8.04M
Cap. Flow
+$183M
Cap. Flow %
64.2%
Top 10 Hldgs %
60.71%
Holding
48
New
9
Increased
9
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$12M
2
AVBP icon
ArriVent BioPharma
AVBP
+$4.49M
3
FENC icon
Fennec Pharmaceuticals
FENC
+$4.41M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$3.86M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$2.49M

Top Sells

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$14.2M
2
CYTK icon
Cytokinetics
CYTK
+$12.7M
3
VRNA
Verona Pharma
VRNA
+$10.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$9.52M
5
GUTS icon
Fractyl Health
GUTS
+$7.43M

Sector Composition

Rank Sector Weight
1 Healthcare 96.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXL icon
26
PUT
Anavex Life Sciences
AVXL
$232M
$1.88M 0.66%
+1,168,600
New +$7.16M
RGNT
27
Regentis Biomaterials
RGNT
$14.5M
$1.7M 0.6%
+251,510
New +$1.73M
XNTK icon
28
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
$1.35M 0.47%
1,937,600
-190,700
-9% -$53.3M
TRVI icon
29
Trevi Therapeutics
TRVI
$2.57B
$1.25M 0.44%
100,000
– –
OEF icon
30
PUT
iShares S&P 100 ETF
OEF
$19.8B
$1.11M 0.39%
200,000
– –
NRXS icon
31
Neuraxis
NRXS
$83.5M
$1.04M 0.37%
+286,138
New +$855K
KURA icon
32
Kura Oncology
KURA
$901M
$1.04M 0.37%
100,000
– –
GUTS icon
33
Fractyl Health
GUTS
$127M
$849K 0.3%
385,731
-4,614,269
-92% -$7.43M
BFRI icon
34
Biofrontera
BFRI
$13.4M
$650K 0.23%
1,140,764
– –
AVBP icon
35
CALL
ArriVent BioPharma
AVBP
$1.4B
$540K 0.19%
+107,900
New +$2.25M
VSTM icon
36
CALL
Verastem
VSTM
$534M
$160K 0.06%
268,600
-377,900
-58% -$3.37M
QURE icon
37
CALL
uniQure
QURE
$2.63B
$95K 0.03%
+100,000
New +$3.86M
REPL icon
38
CALL
Replimune Group
REPL
$724M
$11.5K ﹤0.01%
230,900
-280,500
-55% -$2.38M
VKTX icon
39
CALL
Viking Therapeutics
VKTX
$4.05B
$2K ﹤0.01%
+100,000
New +$3.54M
ATXS
40
DELISTED
Astria Therapeutics
ATXS
– –
-1,542,520
Closed -$1.11M
IDYA icon
41
CALL
IDEAYA Biosciences
IDYA
$3.54B
– –
-35,900
Closed -$237K
IDYA icon
42
IDEAYA Biosciences
IDYA
$3.54B
– –
-350,000
Closed -$9.52M
QURE icon
43
uniQure
QURE
$2.63B
– –
-125,000
Closed -$4.82M
RZLT icon
44
CALL
Rezolute
RZLT
$476M
– –
-263,100
Closed -$546K
RZLT icon
45
Rezolute
RZLT
$476M
– –
-1,807,202
Closed -$14.2M
SRRK icon
46
PUT
Scholar Rock
SRRK
$5.86B
– –
-100,000
Closed -$10K
VRNA
47
DELISTED
Verona Pharma
VRNA
– –
-100,000
Closed -$10.7M
ATYR
48
PUT
aTyr Pharma
ATYR
$48M
– –
-1,570,200
Closed -$4.47M
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return

Rosalind Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Rosalind Advisors held 48 positions worth $285M, down 2.7% from $293M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Rosalind Advisors deployed $183M of net new capital in Q4 2025, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Replimune Group: 1,410,497 shares worth $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $12.7M trimmed.

  • Rosalind Advisors's largest Q4 2025 buy was Replimune Group: 1,410,497 shares worth $13.7M.
  • Rosalind Advisors added most to Fennec Pharmaceuticals in Q4 2025, an estimated $4.41M increase.
  • Rosalind Advisors's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $12.7M.
  • Rosalind Advisors fully exited Rezolute in Q4 2025, selling an estimated $14.2M.
  • Rosalind Advisors's ten largest holdings make up 61% of its $285M portfolio in Q4 2025.
  • Rosalind Advisors opened 9 new positions and closed 9 in Q4 2025.
  • Rosalind Advisors's portfolio value fell 2.7% quarter-over-quarter to $285M.

Based on Rosalind Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.